PLSE at a glance
PULSE BIOSCIENCES, INC. (PLSE, SEC CIK 1625101) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as September 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350,000 and a net loss of $72.8 million. Diluted EPS was -$1.08.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding PULSE BIOSCIENCES, INC. (PLSE) shares worth $525.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Teplitsky Liane Rae on September 1, 2026 of 1,001 shares at $49.95 per share.
- In the last 90 days, PLSE insiders reported 4 open-market purchases ($200K) and 0 open-market sales ($0) on Form 4, a net purchase of $200K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $350K
- 10-K XBRL
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$200K
- 13F holders
- 25 funds
- $525.8M · +1 vs prior quarter
- Latest 8-K
- Nov 6, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Quarterly revenue $0.4M, up $0.3M YoY from $0.1M, entirely from limited Vybrance sales
- Operating margin not disclosed; operating loss $24.3M vs $20.4M YoY
- Vybrance best-performing product line, revenue $0.4M versus $0.1M YoY
- Cash, equivalents and marketable securities $189.2M; operating cash use $48.6M for nine months
- Management expects additional losses, plans near-term capital raising, cites financing access and market conditions as headwinds
Risk Factors
- New AI compliance risk triggered by expanded internal use of generative AI and machine learning, including EU AI Act and evolving FDA requirements
- Regulatory review delays heightened by FDA workforce reductions, voluntary departures, and policy uncertainty since January 2025
- Near-term adoption risk: surgeons have been slow to adopt the Vybrance System due to limited clinical data and reimbursement uncertainty
- Liquidity risk: additional capital required, with armed conflicts and tariffs potentially restricting financing availability or increasing dilution
- Cybersecurity risk: limited resources and no redundant information technology across all systems increase vulnerability to disruptive incidents
AI summary of the PLSE 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules
- 86% achieved the primary endpoint, at least 50% nodule-volume reduction
Item EX-99.1: Item EX-99.1
- Interim six-month PRECISE-BTN results support clinical efficacy: 86% of 43 evaluated patients achieved at least 50% nodule reduction
- Median nodule volume reduction reached 72%, with improvement beginning by one month after a single treatment
Item 2.02: Results of Operations and Financial Condition
- Fiscal quarter ended September 30, 2026 results announced
- Financial and operational details provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q3 revenue $0.4M versus $0.1M, but controlled Vybrance launch continues through Q4 2027
- NANOPULSE-AF enrollment complete: 169 evaluable patients across 15 sites, three months ahead of plan
Item 8.01: Other Events
- Commercial and clinical partnership with Clayman Thyroid Center and affiliates in Tampa, Florida
- Partnership will evaluate clinical utility of Pulse’s proprietary nPulse Vybrance Percutaneous Electrode System
AI summaries of PLSE 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for PLSE
Don't miss the next PLSE filing
- Alerts as it files. A push when PLSE files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut PLSE, by share count.
- Ask anything. An AI agent that reads every PLSE filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Teplitsky Liane Rae | Buy | Sep 1, 2026 | 1,001 | $49.95 |
| Teplitsky Liane Rae | Buy | Aug 31, 2026 | 1,024 | $48.80 |
| Teplitsky Liane Rae | Buy | Aug 28, 2026 | 1,034 | $48.35 |
| Teplitsky Liane Rae | Buy | Aug 26, 2026 | 1,036 | $48.23 |
| Teplitsky Liane Rae | A | Aug 8, 2026 | 700,000 | - |
| Teplitsky Liane Rae | A | Aug 8, 2026 | 200,000 | - |
| Zanganeh Mahkam | A | Jun 11, 2026 | 30,000 | - |
| Sainz Maria | A | Jun 11, 2026 | 3,793 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $350K |
| Operating Income | - | -$56.3M | -$76.9M |
| Net Income | -$42.2M | -$53.6M | -$72.8M |
| Op. Margin | - | - | -21982.6% |
| Net Margin | - | - | -20794.6% |
| Balance Sheet | |||
| Total Assets | $59.2M | $132.5M | $94.5M |
| Equity | - | $114.9M | $80.7M |
| ROE | - | -46.7% | -90.2% |
| Per Share | |||
| EPS | $-0.88 | $-0.92 | $-1.08 |
| Cash Flow | |||
| Operating CF | - | -$36.3M | -$54.1M |
| CapEx | $121K | $125K | $315K |
Source: XBRL data in PULSE BIOSCIENCES, INC. (PLSE)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate PLSE share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $525.8M |
| Q2 2026 | 24 | $175.2M |
| Q1 2026 | 19 | $91.3M |
| Q4 2025 | 15 | $56.7M |
| Q3 2025 | 17 | $72.0M |
| Q2 2025 | 18 | $63.9M |
| Q1 2025 | 18 | $43.4M |
| Q4 2024 | 12 | $38.5M |
- T. Rowe Price Group+2.04M (+273%)
- Citadel Advisors LLC+857.9K (+137%)
- JPMorgan Chase & Co+513.6K (+6123%)
- BlackRock+207.2K (+14%)
- Vanguard Capital Management LLC+149.3K (+19%)
- Allstate−13.9K (-59%)
- Wells Fargo & Co−12.1K (-56%)
- Citigroup−7.2K (-78%)
- Mangrove Partners−7.0K (-23%)
- PNC Financial Services−1.4K (-99%)
- Ameriprise Financial+31.0K
- Prudential Financial+5.3K
- FMR LLC (Fidelity)−13.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
PLSE filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 6, 2026 | - | Analysis | - |
| 10-Q | Nov 5, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 5, 2026 | - | Analysis | - |
| 8-K | Oct 14, 2026 | - | Analysis | - |
| 8-K | Oct 7, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 2, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 11, 2026 | - | - | |
| 4 | May 11, 2026 | - | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
PLSE SEC filings: frequently asked questions
Are PLSE insiders buying or selling?
In the last 90 days, PULSE BIOSCIENCES, INC. (PLSE) officers, directors and 10% owners reported 4 open-market purchases worth $199,937 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold PLSE stock?
As of September 30, 2026, the largest PULSE BIOSCIENCES, INC. (PLSE) holders among the 13F filers tracked by SignalX were T. Rowe Price Group ($139.3 million), BlackRock ($83.6 million), Citadel Advisors LLC ($74.1 million), Bank of America Corp ($73.2 million), Vanguard Capital Management LLC ($46.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was PLSE's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), PULSE BIOSCIENCES, INC. (PLSE) reported revenue of $350,000 and a net loss of $72.8 million. Diluted EPS was -$1.08. The figures come from the XBRL data in the 10-K.
What did PLSE report in its latest 8-K?
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K on November 6, 2026 reporting Item 8.01 (Other Events). Interim six-month data from 43 patients in PRECISE-BTN supports nPulse Vybrance for symptomatic benign thyroid nodules.
What are the latest PLSE SEC filings?
PULSE BIOSCIENCES, INC. (PLSE) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on September 2, 2026.
What is PLSE's SEC CIK number?
PULSE BIOSCIENCES, INC. (PLSE)'s SEC Central Index Key (CIK) is 1625101. EDGAR lists every PLSE filing under that number.
Ask anything about PLSE
The research agent reads PLSE's filings, financials, insider trades and 13F holders, then answers with sources.